Shares of Endologix, Inc. (NASDAQ:ELGX) have been assigned a consensus recommendation of “Hold” from the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and eleven have given a hold recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $6.33.
Several equities research analysts recently issued reports on ELGX shares. Zacks Investment Research upgraded Endologix from a “hold” rating to a “strong-buy” rating and set a $5.75 price objective on the stock in a report on Monday, July 24th. Royal Bank Of Canada reiterated a “hold” rating and issued a $5.00 price objective on shares of Endologix in a report on Monday, July 31st. Stifel Nicolaus set a $6.00 price objective on Endologix and gave the company a “hold” rating in a report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $5.00 price objective on Endologix and gave the company a “hold” rating in a report on Thursday, August 3rd. Finally, Canaccord Genuity reiterated a “hold” rating on shares of Endologix in a report on Friday, August 4th.
Hedge funds and other institutional investors have recently modified their holdings of the business. American International Group Inc. increased its holdings in Endologix by 7.1% during the 1st quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock worth $361,000 after purchasing an additional 3,290 shares during the period. Camber Capital Management LLC increased its holdings in Endologix by 65.1% during the 1st quarter. Camber Capital Management LLC now owns 6,000,000 shares of the medical instruments supplier’s stock worth $43,440,000 after purchasing an additional 2,365,000 shares during the period. Iguana Healthcare Management LLC purchased a new stake in Endologix during the 1st quarter worth about $1,086,000. Endurant Capital Management LP purchased a new stake in Endologix during the 1st quarter worth about $2,425,000. Finally, MARSHALL WACE ASIA Ltd purchased a new stake in Endologix during the 1st quarter worth about $323,000.
Endologix (NASDAQ:ELGX) traded down 0.78% during trading on Wednesday, hitting $5.06. The stock had a trading volume of 352,984 shares. The company’s market cap is $422.18 million. The firm has a 50 day moving average of $4.68 and a 200-day moving average of $5.26. Endologix has a one year low of $4.08 and a one year high of $12.74.
Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. The firm had revenue of $48.60 million for the quarter, compared to the consensus estimate of $47.58 million. Endologix had a negative return on equity of 46.32% and a negative net margin of 40.77%. The company’s quarterly revenue was down 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.20) EPS. Equities analysts anticipate that Endologix will post ($0.62) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Endologix, Inc. (ELGX) Given Average Recommendation of “Hold” by Brokerages” was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.themarketsdaily.com/2017/10/17/endologix-inc-elgx-given-average-recommendation-of-hold-by-brokerages.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.